rs12304921 — SLC11A2

Intronic variant in SLC11A2 (DMT1), the primary intestinal iron transporter, associated with altered iron absorption regulation and T2DM susceptibility through the iron-beta-cell axis

See your personal result for SLC11A2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC11A2 rs12304921 — Iron's Gateway and Diabetes Risk

The SLC11A2 gene encodes Divalent Metal Transporter 1 (DMT1)11 Divalent Metal Transporter 1 (DMT1)
also known as NRAMP2; the primary transporter for ferrous iron across intestinal epithelial cells and from endosomes into the cytosol, the most important protein controlling how much dietary iron enters your body. Located at chromosome 12q13.12, SLC11A2 is expressed in the duodenum, liver, kidney, and — critically for diabetes risk — in pancreatic beta cells, where iron availability directly governs insulin production and secretion. The intronic variant rs12304921 (G allele, ~17% in Europeans) lies within a regulatory region of the gene and has been genotyped in multiple type 2 diabetes (T2DM) genome-wide association studies, pointing to the SLC11A2 locus as a contributor to diabetes susceptibility through the iron-homeostasis pathway.

The Mechanism

DMT1 operates as the gatekeeper for non-heme dietary iron absorption in the duodenum: it transports ferrous iron (Fe²⁺) across the apical brush border membrane of enterocytes. Inside the cell, ferroportin then exports iron into the bloodstream. The balance between DMT1 expression (import) and ferroportin (export) determines systemic iron load. Critically, the SLC11A2 gene produces two major isoforms via alternative 3′ splicing: one containing an iron-responsive element (IRE)22 iron-responsive element (IRE)
a stem-loop structure in the 3′ UTR that stabilizes the mRNA when cellular iron is low, allowing compensatory upregulation of iron absorption in its 3′ UTR, and one lacking this element. Intronic variants near splice regulatory sequences — as rs12304921 may be — can shift the ratio between these two isoforms, altering the body's ability to sense and respond to iron status. When the IRE-containing isoform is suppressed, the body loses its adaptive capacity to upregulate iron absorption during deficiency — or, conversely, to downregulate it during overload.

Beta cells are particularly vulnerable to iron dysregulation. Pancreatic beta cells express high levels of DMT1 and accumulate iron more readily than neighboring alpha cells due to low ferroportin expression. Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%33 Iron deprivation in isolated islets reduces glucose-stimulated insulin secretion by 45%
Martínez-García et al. Cell Metab 2020; n=purified human islet subsets, while iron excess causes oxidative damage via Fenton chemistry, impairing glucose sensing and triggering beta-cell apoptosis. Transcriptome analyses comparing T2DM and control tissue have found that SLC11A2 is significantly downregulated in T2DM samples, and its expression level correlates positively with 113 of 154 insulin-secretion genes — suggesting that disrupted DMT1 function contributes to the beta-cell failure characteristic of T2DM.

The Evidence

rs12304921 was included in the genotyping arrays of several landmark T2DM GWAS studies, including the Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS44 Wellcome Trust Case Control Consortium (WTCCC) 7-disease GWAS
n=14,000 cases, 3,000 controls across seven diseases including T2DM and a cumulative risk SNP study in Han Chinese55 cumulative risk SNP study in Han Chinese
Qian et al. PLoS One 2015; n=996 T2DM cases, 998 controls. These studies establish that the SLC11A2 locus is relevant to T2DM genetic architecture across diverse populations, particularly given the notably higher G allele frequency in East Asian populations (~50%) compared to Europeans (~17%).

A Turkish case-control study examined SLC11A2 intronic polymorphisms directly in 100 T2DM patients versus 100 healthy controls and found that the homozygous risk genotype was significantly associated with T2DM risk under a recessive model (P=0.030 for homozygotes; P=0.037 recessive model)66 (P=0.030 for homozygotes; P=0.037 recessive model)
Ozbayer et al. J Genet 2018, PMID 30555088, with the risk genotype carriers showing higher blood iron levels — consistent with disrupted iron regulation as the underlying mechanism.

At the gene-expression level, a transcriptome meta-analysis found that SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue77 SLC11A2 and TFRC (transferrin receptor) are significantly downregulated in T2DM tissue
Yang et al. Diabetol Metab Syndr 2023, with SLC11A2 expression positively correlating with 73% of insulin-secretion genes. A meta-analysis of iron biomarkers and T2DM found that elevated serum ferritin (a marker of iron stores) is associated with a 70% increased T2DM risk, and interventional phlebotomy studies show that reducing iron stores improves insulin sensitivity and beta-cell function in pre-diabetic individuals.

At this time, rs12304921 has not reached genome-wide significance as a standalone T2DM locus, and the evidence is classified as emerging. The biological mechanism connecting SLC11A2 to T2DM is well-established; the specific contribution of this intronic variant requires further functional characterization.

Practical Implications

G allele carriers have potential for altered iron absorption regulation, which may manifest as higher baseline iron stores or impaired adaptive upregulation during iron deficiency. Given the U-shaped relationship between iron status and T2DM risk — both very low and very high iron are harmful — monitoring serum ferritin is the key actionable insight. GG homozygotes carry the greatest potential for altered iron homeostasis. Avoiding supplemental iron unless deficiency is confirmed by blood tests is particularly important, since excess iron loads the pancreatic beta cells with ferrous iron that generates oxidative damage.

Interactions

SLC11A2 function interacts with several other iron-homeostasis genes: HFE (rs1799945, C282Y) mutations cause hereditary hemochromatosis through hepcidin dysregulation upstream of DMT1; TMPRSS6 (rs855791) regulates hepcidin synthesis, the master iron hormone that suppresses DMT1 at the duodenum. Carriers of both rs12304921 G and HFE C282Y may accumulate iron more rapidly than either variant alone predicts, as DMT1 dysregulation combined with reduced hepcidin signaling removes two separate brakes on iron absorption. These potential gene-gene interactions warrant a combined monitoring approach in carriers.

Nutrient Interactions

iron altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Common genotype — standard SLC11A2 iron transport regulation

You carry two copies of the common A allele at rs12304921 in the SLC11A2 gene. Your DMT1 iron transporter is regulated through the standard balance of IRE-containing and non-IRE isoforms. About 69% of people globally share this genotype (84% of Europeans). Your iron absorption adapts normally to dietary intake and body iron stores, and your T2DM risk through the SLC11A2 iron pathway is at population baseline.

AG Intermediate

One G allele — potentially altered iron absorption regulation

The AG heterozygous state means one SLC11A2 allele produces iron transporter protein with the reference regulatory context, while the other carries the G variant. The net effect on DMT1 isoform balance is intermediate: some shift in the IRE/non-IRE ratio is possible, but the functional SLC11A2 allele provides a degree of compensation.

The most clinically important implication is avoiding unnecessary iron supplementation, which could lead to iron accumulation that the SLC11A2 regulatory system may not efficiently counteract. Ferritin above 200 ng/mL (for women) or 300 ng/mL (for men) signals excess iron stores that warrant attention. In the context of T2DM prevention, there is emerging evidence that maintaining iron stores in the lower-normal range supports optimal beta-cell function.

GG High Risk

Two G alleles — greatest potential for altered iron absorption regulation

With both copies of SLC11A2 carrying the G variant, the regulatory balance between IRE-containing and non-IRE DMT1 isoforms is most likely to be shifted. The IRE-containing isoform normally upregulates DMT1 expression when iron is low (protecting against deficiency) and downregulates it when iron is high (protecting against overload). A shift toward non-IRE expression impairs this adaptive feedback loop.

Pancreatic beta cells are particularly sensitive to iron dysregulation: they express high DMT1 levels, accumulate iron readily, and show impaired insulin secretion under both iron deficiency and iron overload. The SLC11A2 downregulation documented in T2DM transcriptome data — where SLC11A2 expression correlates positively with 113 of 154 insulin-secretion genes — points to DMT1 as a key node in the iron-beta-cell-insulin axis.

Annual ferritin monitoring, avoidance of supplemental iron, and dietary strategies that modulate iron absorption (inhibitors with iron-rich meals) are the practical tools available to GG carriers to maintain iron stores in the metabolically optimal range.